DPP-4 resistance comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-26. Numbers and descriptions here follow the published literature rather than marketing material.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
==== Vitamin K ==== Vitamin K is an essential factor to the hepatic gamma-glutamyl carboxylase that adds a carboxyl group to glutamic acid residues on factors II, VII, IX and X, as well as Protein S, Protein C and Protein Z. In adding the gamma-carboxyl group to glutamate residues on the immature clotting factors, Vitamin K is itself oxidized. Another enzyme, Vitamin K epoxide reductase (VKORC), reduces vitamin K back to its active form. Vitamin K epoxide reductase is pharmacologically important as a target of anticoagulant drugs warfarin and related coumarins such as acenocoumarol, phenprocoumon, and dicumarol. These drugs create a deficiency of reduced vitamin K by blocking VKORC, thereby inhibiting maturation of clotting factors. Vitamin K deficiency from other causes (e.g., in malabsorption) or impaired vitamin K metabolism in disease (e.g., in liver failure) lead to the formation of PIVKAs (proteins formed in vitamin K absence), which are partially or totally non-gamma carboxylated, affecting the coagulation factors' ability to bind to phospholipid.
internal carotid the supratrochlear artery to the midline forehead. The supratrochlear artery is a branch of the ophthalmic branch of the internal carotid artery. the supraorbital artery to the lateral forehead and scalp as far up as the vertex. The supraorbital artery is a branch of the ophthalmic branch of the internal carotid artery. external carotid the superficial temporal artery gives off frontal and parietal branches to supply much of the scalp the occipital artery which runs posteriorly to supply much of the posterior aspect of the scalp the posterior auricular artery, a branch of the external carotid artery, ascends behind the auricle to supply the scalp above and behind the auricle. Because the walls of the blood vessels are firmly attached to the fibrous tissue of the superficial fascial layer, cut ends of vessels here do not readily retract; even a small scalp wound may bleed profusely. Venous drainage The veins of the scalp accompany the arteries and thus have similar names, e.g. Supratrochlear and supraorbital veins, which unite at the medial angle of the eye, and form the angular vein, which further continues as the facial vein. The superficial temporal vein descends in front of the tragus, enters the parotid gland, and then joins the maxillary vein to form the retromandibular vein. The anterior part of it unites with the facial vein to form the common facial vein, which drains into jugular vein, and ultimately to the subclavian vein. The occipital vein terminates to the sub-occipital plexus.
Their hypotheses were confirmed in the mid-1970s and 1980s by Erwin Neher and Bert Sakmann, who developed the technique of patch clamping to examine the conductance states of individual ion channels. In the 21st century, researchers are beginning to understand the structural basis for these conductance states and for the selectivity of channels for their species of ion, through the atomic-resolution crystal structures, fluorescence distance measurements and cryo-electron microscopy studies. Julius Bernstein was also the first to introduce the Nernst equation for resting potential across the membrane; this was generalized by David E. Goldman to the eponymous Goldman equation in 1943. The sodium–potassium pump was identified in 1957 and its properties gradually elucidated, culminating in the determination of its atomic-resolution structure by X-ray crystallography. The crystal structures of related ionic pumps have also been solved, giving a broader view of how these molecular machines work.
== Further reading == Economy, Elizabeth C. (2018). The Third Revolution: Xi Jinping and the New Chinese State. Oxford University Press. ISBN 978-0-19-086607-5. Goodman, David S. G. (2015). Handbook of the Politics of China. Edward Elga. ISBN 978-1-78254-437-1. Li, Cheng (2014a). "Xi Jinping's Inner Circle (Part 2: Friends from Xi's Formative Years)" (PDF). Hoover Institution. Archived (PDF) from the original on 26 September 2020. Retrieved 15 July 2020. Simon, Denis Fred; Cong, Cao (2009). China's Emerging Technological Edge: Assessing the Role of High-End Talent. Cambridge University Press. ISBN 978-0-521-88513-3. Yang, Rufeng (2014). 習近平如何改變中國 [How Xi Jinping is changing China]. China Interpretation Series (in Chinese). Bonfire Limited. p. 12. ISBN 978-986-5721-05-3. Retrieved 23 August 2024. Zhu, Pengpeng (2007). 谜一样的人生 [A Mysterious Life] (in Chinese). Tianma Publishing. ISBN 978-0-9787999-2-2. Retrieved 23 August 2024.
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
Sources: en.wikipedia.org
Nalbuphine is a semisynthetic mixed agonist/antagonist opioid modulator of the phenanthrene or morphinan series. It is structurally related to the widely used opioid antagonists naloxone and naltrexone, and to the potent opioid analgesic oxymorphone. Nalbuphine binds with high affinity to the MOR and KOR, and has relatively low affinity for the DOR. It behaves as a moderate-efficacy partial agonist (or mixed agonist/antagonist) of the MOR and as a high-efficacy partial agonist of the KOR. Nalbuphine has weak or no affinity for the sigma receptor(s) (e.g., Ki > 100,000 nM). Nalbuphine is said to be more morphine-like at lower doses. However at higher doses, it produces more sedation, drunkenness, dysphoria, and dissociation. As such, its effects are dose-dependent. Such effects include sedation (21–36%), dizziness or vertigo (5%), lightheadedness (1%), anxiety (<1%), dysphoria (<1%), euphoria (<1%), confusion (<1%), hallucinations (<1%), depersonalization (1%), unusual dreams (<1%), and feelings of "unreality" (<1%). Nalbuphine is a potent analgesic. Its analgesic potency is essentially equivalent to that of morphine on a milligram basis, which is based on relative potency studies using intramuscular administration (Beaver et al. 1978). Oral administered nalbuphine is reported to be three times more potent than codeine (Okun et al. 1982). Clinical trials studied single dose experimental oral immediate release nalbuphine tablets for analgesic efficacy over a four- to six-hour time period following administration.
By 2015, SF Holding's revenue reached RMB 47.3 billion, up 23.6% year-on-year, and its profit was RMB 1.967 billion, up 80% year-on-year. Its core profit after deducting non-recurring business was RMB 1.623 billion, up 76% year-on-year. Its gross profit margin increased from 17.55% to 20.42%. Its air fleet increased to over 30 all-cargo charter flights, with over 30,000 business locations, over 200 hubs, and more than 15,000 operating vehicles. On May 23, 2016, SF Express applied for a backdoor listing on the Shenzhen A-share market. Maanshan Dingtai Rare Earth & New Material Co., Ltd. announced that it would acquire 100% of SF Holding for RMB 44.3 billion, of which Maanshan Dingtai Rare Earth & New Material Co., Ltd. would pay SF Holding shareholders by issuing 3.95 billion new shares at RMB 10.76 per share. After the transaction is completed, Mingde Holding, controlled by Wang Wei, the founder and CEO of SF Express, would hold 64.58% of the shares of the new company. The company was listed on the Shenzhen Stock Exchange in January 2017. In February of the same year, Maanshan Dingtai Rare Earth & New Material Co., Ltd. was officially renamed SF Holding Co., Limited. On February 9, 2018, SF Holding invested RMB 45.9 billion to participate in the investment and construction of Ezhou Airport. In July 2018, SF Holding completed the acquisition of a 75% stake in HAVI China Holding LLC, planning to expand its cold chain logistics business in Mainland China, Hong Kong and Macau. In the same year, it completed the acquisition of Guangdong Xinbang Logistics Co., Ltd.
Edwards Ltd is a British multinational vacuum pump and exhaust gas management systems manufacturer. Its headquarters are in Burgess Hill, UK, and has been part of the Atlas Copco Group since 2014. Edwards holds 1,700 patents, including for dry (oil-free) vacuum pumps, and produces equipment used for manufacturing semiconductors, scientific research, freeze drying and other industries. Its pumps remove contaminants at CERN's Large Hadron Collider. Manufacturing is predominantly handled by subsidiary businesses in the Czech Republic, South Korea, USA and China. Edwards' global research and development facilities remain in the UK. Major customers in 2012 included Samsung, Hynix, Agilent and LG.
===== MeSH D08.811.682.660 – oxidoreductases acting on ch-ch group donors ===== MeSH D08.811.682.660.150 – acyl-coa dehydrogenases MeSH D08.811.682.660.150.100 – acyl-coa dehydrogenase MeSH D08.811.682.660.150.150 – acyl-coa dehydrogenase, long-chain MeSH D08.811.682.660.150.200 – acyl-CoA oxidase MeSH D08.811.682.660.150.300 – butyryl-coa dehydrogenase MeSH D08.811.682.660.200 – cholestenone 5alpha-reductase MeSH D08.811.682.660.250 – coproporphyrinogen oxidase MeSH D08.811.682.660.275 – dihydrodipicolinate reductase MeSH D08.811.682.660.300 – dihydroorotate oxidase MeSH D08.811.682.660.325 – dihydrouracil dehydrogenase (nad+) MeSH D08.811.682.660.350 – dihydrouracil dehydrogenase (nadp) MeSH D08.811.682.660.385 – electron transport complex ii MeSH D08.811.682.660.385.500 – succinate dehydrogenase MeSH D08.811.682.660.387 – enoyl-(acyl-carrier-protein) reductase (nadh) MeSH D08.811.682.660.390 – enoyl-(acyl-carrier protein) reductase (nadph, b-specific) MeSH D08.811.682.660.425 – Glutaryl-CoA dehydrogenase MeSH D08.811.682.660.462 – isovaleryl-coa dehydrogenase MeSH D08.811.682.660.490 – 15-oxoprostaglandin 13-reductase MeSH D08.811.682.660.500 – prephenate dehydrogenase MeSH D08.811.682.660.600 – protoporphyrinogen oxidase MeSH D08.811.682.660.750 – succinate dehydrogenase MeSH D08.811.682.660.900 – testosterone 5-alpha-Reductase
=== Early life === Because of his father's career as a foreign service officer, much of Platt's childhood was spent in Asia and Washington, D.C. Platt attended twelve different schools, including the American School in Japan, and has said "Even now I find myself envying people who have neighborhoods and roots." Platt's family made frequent trips back to Washington, where they held Redskins season tickets. Platt is also a fan of the Boston Red Sox. When he was nine years old, Platt and his family visited the Kennedy Center in Washington, where he watched a performance that helped inspire his acting career. "One of the performances that really made me want to be an actor started out with this probably 20-minute rambling, drunken monologue by this bum. And it was a young Morgan Freeman. I'll never forget it. This guy was just so riveting. He stood there on stage alone before the curtain went up, and he held this audience utterly rapt. Including myself, obviously." According to Platt, drama departments gave his childhood some stability, "It was something of a survival mechanism, in that it gave me a little subculture to plug into wherever I ended up. Kids need that. I certainly did."
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.